AMSTERDAM, Nov. 11, 2016 /PRNewswire/ -- Royal Philips
(NYSE: PHG; AEX: PHIA), a global leader in health technology, and
N-of-One, Inc., the leader in clinical interpretation of molecular
tests in oncology, today announced they are teaming up to
enhance the capabilities of Philips' IntelliSpace Genomics
solution. The two companies will collaborate on the clinical
analysis, annotation and interpretation of oncology cases processed
through Philips' new precision medicine solution for oncology. This
healthcare informatics solution integrates genomic information with
full patient context to empower clinicians with precision
diagnostics and therapeutics, to enable them to measure the success
of precision healthcare programs.
Profiling tumors using genomic information is critical for
complex cancer cases, yet challenges remain in rapidly and
accurately interpreting genomic findings in the context of a
patient's condition. While most cancer patients have thousands of
gene variants and mutations, only a small number actually drive the
individual's specific cancer or may have actionable therapeutic
implications for a particular patient.
The Philips IntelliSpace Genomics solution, which uniquely
integrates complete patient information, is coupled with N-of-One's
rich experience and extensive knowledge-bases. For the first time,
clinicians will have full access to N-of-One's variant database
during the case filtering and interpretation process, providing
them ready access to the vast amount of available reference
literature, guidelines, and evidence, in a fully interactive
framework. The aim is to help clinicians determine which treatment
options, clinical trials or medications are best suited to a
specific case.
"N-of-One has been a pioneer in the field, and by integrating
their information directly on our IntelliSpace Genomics solution,
we aim to reduce the turn-around time for these cancer cases," said
Louis Culot, General Manager,
Philips Genomics. "Providing specialists with the most relevant
treatment options through the analysis of each patient's unique
molecular profile will help extend the reach and scale of
personalized medicine."
"Philips is a clear leader in clinical informatics, integrating
and managing big data in the healthcare settings," said
Chris Cournoyer, CEO of N-of-One.
"We believe that incorporating N-of-One's Variant Database along
with its patient case analysis and interpretation services will be
further enabled by tight integration with this leading digital
health solution."
In addition to integrating and processing genomic information
from an array of high-throughput platforms, IntelliSpace Genomics
provides full traceability of data processing and cases for
unprecedented reproducibility and audit of interpretation and
results. Uniquely, it can also leverage existing patient
information available in healthcare settings including past
treatment history and lab results, while providing analytics to
empower precision healthcare decision support.
Earlier today, Philips and Westchester Medical Center
(WMCHealth) Health Network announced the launch of WMCHealth's new
precision medicine initiative for personalized cancer treatment,
which will use Philips' IntelliSpace Genomics solution to integrate
large-scale genomic analysis with extensive patient clinical data.
The WMCHealth precision medicine initiative will be covering 15
hospitals and oncology practices in the New York Metro area and Hudson Valley.
For further information, please contact:
Kathy O'Reilly
Philips Group Communications
Tel.: +1 978-659-2638
E-mail: Kathy.Oreilly@philips.com
Twitter: @kathyoreilly
Joost Maltha
Philips Communications Healthcare Informatics, Solutions and
Services
Tel.: +31 610-55-8116
E-mail: Joost.Maltha@philips.com
Twitter: @JoostMaltha
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2015 sales of
EUR 16.8 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
About N-of-One
N-of-One is the leader in identifying
patient-specific therapeutic options for precision medicine in
oncology by leveraging its proprietary knowledgebase and its team
of oncologists and Ph.D. scientists to integrate molecular data
from multiple tests. Using N-of-One solutions can standardize and
accelerate genomic clinical interpretation and molecular decision
support while saving time and money. N-of-One's solutions have
provided therapeutic options, including clinical trials, for tens
of thousands of patient cases across hundreds of cancer types.
N-of-One partners with leading hospital systems, cancer centers,
and commercial labs around the world. For more information, please
visit www.n-of-one.com or call +1 617-202-9808.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-teams-up-with-molecular-decision-support-leader-n-of-one-to-speed-up-clinical-interpretation-of-cancer-genomics-300361406.html
SOURCE Royal Philips